Communications Medicine (Aug 2024)

A micro-disc-based multiplex method for monitoring emerging SARS-CoV-2 variants using the molecular diagnostic tool Intelli-OVI

  • Md Belal Hossain,
  • Yoshikazu Uchiyama,
  • Samiul Alam Rajib,
  • Akhinur Rahman,
  • Mitsuyoshi Takatori,
  • Benjy Jek Yang Tan,
  • Kenji Sugata,
  • Mami Nagashima,
  • Mamiyo Kawakami,
  • Hitoshi Ito,
  • Ryota Kumagai,
  • Kenji Sadamasu,
  • Yasuhiro Ogi,
  • Tatsuya Kawaguchi,
  • Tomokazu Tamura,
  • Takasuke Fukuhara,
  • Masahiro Ono,
  • Kazuhisa Yoshimura,
  • Yorifumi Satou

DOI
https://doi.org/10.1038/s43856-024-00582-z
Journal volume & issue
Vol. 4, no. 1
pp. 1 – 15

Abstract

Read online

Abstract Background Highly transmissible viruses including SARS-CoV-2 frequently accumulate novel mutations that are detected via high-throughput sequencing. However, there is a need to develop an alternative rapid and non-expensive approach. Here we developed a novel multiplex DNA detection method Intelli-OVI for analysing existing and novel mutations of SARS-CoV-2. Methods We have developed Intelli-OVI that includes the micro-disc-based method IntelliPlex and computational algorithms of objective variant identification (OVI). More than 250 SARS-CoV-2 positive samples including wastewater ones were analysed to verify the efficiency of the method. Results IntelliPlex uses micro-discs printed with a unique pictorial pattern as a labelling conjugate for DNA probes, and OVI allows simultaneous identification of several variants using multidimensional data obtained by the IntelliPlex method. Importantly, de novo mutations can be identified by decreased signals, which indicates that there is an emergence of de novo variant virus as well as prompts the need to design additional primers and probes. We have upgraded probe panel according to the emergence of new variants and demonstrated that Intelli-OVI efficiently identified more than 20 different SARS-CoV-2 variants by using 35 different probes simultaneously. Conclusions Intelli-OVI can be upgraded to keep up with rapidly evolving viruses as we showed in this study using SARS-CoV-2 as an example and may be suitable for other viruses but would need to be validated.